Evaluation of an advanced model reference sliding mode control method for cardiac assist device using a numerical model

A Feasible Method to Control Left Ventricular Assist Devices for Heart Failure Patients: A Numerical Study

Installing and developing a sophisticated control system to optimize left ventricular assist device (LVAD) pump speed to meet changes in metabolic demand is essential for advancing LVAD technology. This paper aims to design and implement a physiological control method for LVAD pumps to provide optimal cardiac output. The method is designed to adjust the pump speed by regulating the pump flow based on a predefined set point (operating point). The Frank–Starling mechanism technique was adopted to control the set point within a safe operating zone (green square), and it mimics the physiological demand of the patient. This zone is predefined by preload control lines, which are known as preload lines. A proportional–integral (PI) controller was utilized to control the operating point within safe limits to prevent suction or overperfusion. In addition, a PI type 1 fuzzy logic controller was designed and implemented to drive the LVAD pump. To evaluate the design method, rest, moderate, and exercise scenarios of heart failure (HF) were simulated by varying the hemodynamic parameters in one cardiac cycle. This evaluation was conducted using a lumped parameter model of the cardiovascular system (CVS). The results demonstrated that the proposed control method efficiently drives an LVAD pump under accepted clinical conditions. In both scenarios, the left ventricle pressure recorded 112 mmHg for rest and 55 mmHg for exercise, and the systematic flow recorded 5.5 L/min for rest and 1.75 L/min for exercise.

NUMERICAL INVESTIGATION ON PRELOAD AND AFTERLOAD SENSITIVITY FOR USING VENTRICULAR ASSIST DEVICE ON HEART FAILURE PATIENTS

A left ventricular assist device (LVAD) is a surgically implanted mechanical pump being used for patients with end-stage heart failure (HF). One of the significant clinical challenges in using LVADs is its remarkable changes in hemodynamic parameters during a change in body position from supine to standing. In standing position, vasodilatation of veins occurs in the legs, which decreases left ventricular end-diastolic pressure, and, in turn, the preload to the LVAD. In this research, a numerical investigation is carried out to evaluate the effect of LVAD in cardiac hemodynamic parameters such as cardiac output (CO) and stroke work (SW) under preload, normal, and afterload conditions. A Proportional–integral–derivative (PID) controller associated with an LVAD pump model and cardiovascular system (CVS) model is developed to study the cardiac hemodynamic and its performance during HF condition by changing system parameters in one cardiac cycle. The performance of the proposed model is then evaluated using a pump cannulae model, real-time status detection of the aortic valve (av), and left ventricular stroke volume. The model parameters associated with HF, including contractility of the left and right ventricle ([Formula: see text] & [Formula: see text]), systemic peripheral resistance ([Formula: see text]) and total blood volume ([Formula: see text]) were set 0.71[Formula: see text]mmHg.s.mL[Formula: see text], 0.53[Formula: see text]mmHg.s.mL[Formula: see text], 1.11[Formula: see text]mmHg.s.mL[Formula: see text] and 5800[Formula: see text]mL, respectively, to allow simulation of HF conditions. The findings of this study show that the CO is increasing linearly with end-diastolic left ventricular volume (LVEDV) and end-diastolic right ventricular volume (RVEDV). However, other vital parameters behavior has a nonlinear relation to CO. Results of this study prove that the LVAD model is more sensitive to preload than afterload condition under different hemodynamical conditions.

Sliding mode controller-observer pair for p53 pathway

A significant loss of p53 protein, an anti-tumour agent, is observed in early cancerous cells. Induction of small molecules based drug is by far the most prominent technique to revive and maintain wild-type p53 to the desired level. In this study, a sliding mode control (SMC) based robust non-linear technique is presented for the drug design of a control-oriented p53 model. The control input generated by conventional SMC is discontinuous; however, depending on the physical nature of the system, drug infusion needs to be continuous. Therefore, to obtain a smooth control signal, a dynamic SMC (DSMC) is designed. Moreover, the boundedness of the zero-dynamics is also proved. To make the model-based control design possible, the unknown states of the system are estimated using an equivalent control based, reduced-order sliding mode observer. The robustness of the proposed technique is assessed by introducing input disturbance and parametric uncertainty in the system. The effectiveness of the proposed control scheme is witnessed by performing in-silico trials, revealing that the sustained level of p53 can be achieved by controlled drug administration. Moreover, a comparative quantitative analysis shows that both controllers yield similar performance. However, DSMC consumes less control energy.